Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
$1.06
+1.0%
$1.35
$0.59
$4.49
$18.04M4748,005 shs109,695 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
+0.95%-5.36%-13.82%-49.28%-54.11%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
1.7929 of 5 stars
3.53.00.00.00.61.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
3.00
Buy$5.00371.70% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
$170K107.12N/AN/A$0.28 per share3.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
-$7.61M-$0.83N/AN/A-6,529.77%-277.92%-245.37%8/14/2025 (Estimated)

Latest NXL, 8CO, 99L, and OU1 Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
-$0.10-$0.15-$0.05-$0.15$0.04 million$0.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
N/A
4.56
4.25

Institutional Ownership

CompanyInstitutional Ownership
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
0.65%

Insider Ownership

CompanyInsider Ownership
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
25.26%
CompanyEmployeesShares OutstandingFree FloatOptionable
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
317.18 million12.84 millionNot Optionable

Recent News About These Companies

Nexalin Technology receives IRB approval in Brazil, begins trial

New MarketBeat Followers Over Time

Media Sentiment Over Time

Nexalin Technology stock logo

Nexalin Technology NASDAQ:NXL

$1.06 +0.01 (+0.95%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$1.06 0.00 (0.00%)
As of 06/24/2025 07:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.